Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for ...

In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next ...

Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the ...

Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...

Why Harris-Walz? The women say they believe Donald Trump, the Republican candidate, would reduce funding for Medicaid and Medicare spending and repeal the Affordable Care Act. They say that would ...

As Massachusetts prepares to vote on a measure that would legalize psilocybin and other plant-based psychedelic substances, ...

The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down. Emerson has ...

After the turbulent reaction to Lykos Therapeutics’ failure to get its MDMA formulation approved, clinicians and industry ...

Lykos Therapeutics is slashing around 75% of its staff following the FDA's decision not to approve its MDMA-assisted therapy for post-traumatic stress disorder (PTSD) last week, with founder Rick ...

Recommended Reading In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD The CEO of Lykos Therapeutics will step down after the company’s efforts to win a milestone approval for ...

The FDA has previously acknowledged its therapeutic potential, granting a new drug application, submitted by Lykos Therapeutics (formerly MAPS Public Benefit Corporation), priority review for ...

The FDA recently declined to approve MDMA-assisted therapy for PTSD, but experts said there are many other treatments on the ...